CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 0.6%

CytomX Therapeutics Inc (NASDAQ:CTMX) rose 0.6% on Wednesday . The stock traded as high as $6.79 and last traded at $6.57, approximately 26,151 shares traded hands during trading. A decline of 95% from the average daily volume of 568,825 shares. The stock had previously closed at $6.53.

CTMX has been the topic of several recent research reports. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 9th. Guggenheim initiated coverage on CytomX Therapeutics in a report on Wednesday, November 27th. They set a “buy” rating and a $16.00 price target on the stock. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. Nomura cut their price target on CytomX Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Finally, Barclays initiated coverage on CytomX Therapeutics in a report on Wednesday, March 4th. They set an “equal weight” rating and a $7.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. CytomX Therapeutics currently has an average rating of “Buy” and an average target price of $13.41.

The business has a 50 day moving average of $6.49 and a 200-day moving average of $7.12. The stock has a market cap of $292.56 million, a PE ratio of -2.85 and a beta of 0.82. The company has a current ratio of 3.54, a quick ratio of 3.54 and a debt-to-equity ratio of 0.49.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.31). The firm had revenue of $8.28 million for the quarter, compared to analysts’ expectations of $15.69 million. CytomX Therapeutics had a negative return on equity of 114.46% and a negative net margin of 177.84%. Research analysts expect that CytomX Therapeutics Inc will post -2.4 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new stake in CytomX Therapeutics during the 4th quarter worth approximately $28,000. Tower Research Capital LLC TRC lifted its position in CytomX Therapeutics by 133.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,856 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 2,202 shares during the period. Bank of Montreal Can lifted its position in CytomX Therapeutics by 42.5% during the 4th quarter. Bank of Montreal Can now owns 5,630 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 1,680 shares during the period. Man Group plc acquired a new stake in CytomX Therapeutics during the 3rd quarter worth approximately $76,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in CytomX Therapeutics during the 4th quarter worth approximately $113,000. Hedge funds and other institutional investors own 79.02% of the company’s stock.

CytomX Therapeutics Company Profile (NASDAQ:CTMX)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: Special Dividends

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.